Advanced search
Publication Cover
Future Microbiology Volume 6, 2011 - Issue 2
Submit an article Journal homepage
452
Views
55
CrossRef citations to date
0
Altmetric
Review

Mycobacterium Leprae–Host-Cell Interactions and Genetic Determinants in Leprosy: an Overview

Roberta Olmo Pinheiro1 Leprosy Laboratory,Oswaldo Cruz Institute, FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro,RJ,Brazil,21040-21360View further author information
,
Jorgenilce de Souza Salles1 Leprosy Laboratory,Oswaldo Cruz Institute, FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro,RJ,Brazil,21040-21360View further author information
,
Euzenir Nunes Sarno1 Leprosy Laboratory,Oswaldo Cruz Institute, FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro,RJ,Brazil,21040-21360View further author information
&
Elizabeth Pereira Sampaio1 Leprosy Laboratory,Oswaldo Cruz Institute, FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro,RJ,Brazil,21040-21360;2 Immunopathogenesis Section,Laboratory of Clinical Infectious Diseases,LCID,National Institutes of Health, NIH,9000 Rockville Pike,Bethesda, MD,20892-21684,USA.Correspondence[email protected]
View further author information
Pages 217-230 | Published online: 02 Mar 2011

Bibliography

  • Noordeen SK : Elimination of leprosy as a public health problem.Indian J. Lepr.66 , 1–10 (1994).
  • Britton WJ , LockwoodDN: Leprosy.Lancet363 , 1209–1219 (2004).
  • Ridley DS , JoplingWH: Classification of leprosy according to immunity. A five-group system.Int. J. Lepr.34 , 255–273 (1966).
  • Van Voorhis WC , KaplanG, SarnoENet al. : The cutaneous infiltrates of leprosy: cellular characteristics and the predominant T-cell phenotypes.N. Engl. J. Med.307 , 1593–1597 (1982).
  • Modlin RL , HofmanFM, TaylorCR, ReaTH: T lymphocyte subsets in the skin lesions of patients with leprosy.J. Am. Acad. Dermatol.8 , 182–189 (1983).
  • Wallach D , FlageulB, BachMA, CottenotF: The cellular content of dermal leprous granulomas: an immuno-histological approach.Int. J. Lepr.52 , 318–326 (1984).
  • WHO: Chemotherapy of leprosy for control programmes. World Health Organ. Tech. Rep. Ser. 675 , 1–33 (1982).
  • Walker SL , LockwoodDN: The clinical and immunological features of leprosy.Br. Med. Bull.77–78 , 103–121 (2006).
  • Lienhardt C , FinePE: Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation?Lepr. Rev.65 , 9–33 (1994).
  • Sarno EN , GrauGE, VieiraLM, NeryJA: Serum levels of tumour necrosis factor-α and interleukin-1 β during leprosy reactional states.Clin. Exp. Immunol.84 , 103–108 (1991).
  • Khanolkar-Young S , RaymentN, BrickellPMet al. : Tumour necrosis factor-α (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions.Clin. Exp. Immunol.99 , 196–202 (1995).
  • Walker SL , LockwoodDN: Leprosy type 1 (reversal) reactions and their management.Lepr. Review79 , 372–386 (2008).
  • Lockwood DN : Steroids in leprosy type 1 reactions: mechanisms of action and effectiveness.Lepr. Rev.71(Suppl.) , S111–S114 (2000).
  • Croft RP , NichollsPG, SteyerbergEW, RichardusJH, WithingtonSG, SmithWC: A clinical prediction rule for nerve function impairment in leprosy patients revisited after 5 years of follow-up.Lepr. Rev.74 , 35–41 (2003).
  • Girdhar BK , GirdharA, ChakmaJK: Advances in the treatment of reactions in leprosy.Indian J. Lepr.79 , 121–134 (2007).
  • Walker SL , WatersMF, LockwoodDN: The role of thalidomide in the management of erythema nodosum leprosum.Lepr. Rev.78 , 197–215 (2007).
  • Sarno EN , NeryJAC, SampaioEP: Is pentoxifylline a viable alternative in the treatment of ENL?Int. J. Lepr.63 , 570–571 (1995).
  • Sales AM , deMatos HJ, NeryJA, DuppreNC, SampaioEP, SarnoEN: Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy.Braz. J. Med. Biol. Res.40 , 243–248 (2007).
  • Kaur I , DograS, NarangT, DeD: Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a ramdomized study.Australas. J. Dermatol.50 , 181–185 (2009).
  • Saber M , Bourassa-FulopC, BouffardD, ProvostN: Canadian case report of erythema nodosum leprosum successfully treated with prednisone and thalidomide.J. Cutan. Med. Surg.14 , 95–99 (2010).
  • Teo SK : Properties of thalidomide and its analogues: implications for anticancer therapy.AAPS J.7 , E14–E19 (2005).
  • Lebrin F , SrunS, RaymondKet al. : Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.Nat. Med.16 , 420–428 (2010).
  • Akhurst RJ : Taking thalidomide out of rehab.Nat. Med.16 , 370–372 (2010).
  • Ito T , AndoH, SuzukiTet al. : Identification of a primary target of thalidomide teratogenicity.Science327 , 1345–1350 (2010).
  • Sampaio EP , SarnoEN, GalillyR, CohnZA, KaplanG: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes.J. Exp. Med.173 , 699–703 (1991).
  • Moreira AL , SampaioEP, ZmuidzinasA, FrindtP, SmithKA, KaplanG: Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation.J. Exp. Med.177 , 1675–1680 (1993).
  • Anderson KC : Lenalidomide and thalidomide: mechanisms of action – similarities and differences.Semin. Hematol.42 , S3–S8 (2005).
  • Sampaio EP , KaplanG, MirandaAet al. : The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum.J. Infect. Dis.168 , 408–414 (1993).
  • Moraes MO , SarnoEN, TelesRMet al. : Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients.J. Invest. Dermatol.115 , 935–941 (2000).
  • Corral LG , MullerGW, MoreiraALet al. : Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity.Mol. Med.2 , 506–515 (1996).
  • Fujimoto H , NoguchiT, KobayashiH, MiyachiH, HashimotoY: Effects of immunomodulatory derivatives of thalidomide (IMiDs) and their analogs on cell-differentiation, cyclooxygenase activity and angiogenesis.Chem. Pharm. Bull. (Tokyo)54 , 855–860 (2006).
  • Gandhi AK , KangJ, CaponeLet al. : Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.Curr. Cancer Drug Targets10 , 155–167 (2010).
  • Lockwood DN : Leprosy elimination: a virtual phenomenon or a reality?BMJ324 , 1516–1518 (2002).
  • Rao AG : Study of leprosy in children.Indian J. Lepr.81 , 195–197 (2009).
  • Balagon MF , CellonaRV, delaCruz ECet al.: Long-term risk of relapse of multibacillary leprosy after completion of 2-year multiple drug therapy (WHO-MDT) in Cebu, Philippines.Am. J. Trop. Med. Hyg.81 , 895–899 (2009).
  • Sampaio EP , CaneshiJRT, NeryJACet al. : Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals.Infect. Immun.63 , 1848–1854 (1995).
  • Nery JAC , SampaioEP, GalhardoMCGet al. : M. leprae–HIV co-infection: pattern of immune response in vivo and in vitro.Indian J. Lepr.72 , 155–167 (2000).
  • Sarno EN , IllarramendiX, NeryJAet al. : HIV–M. leprae interaction: can HAART modify the course of leprosy?Public Health Rep.123 , 206–212 (2008).
  • Deps PD , LockwoodDN: Leprosy occurring as immune reconstitution syndrome.Trans. R. Soc. Trop. Med. Hyg.102 , 966–968 (2008).
  • Couppie P , DomergueV, ClytiEet al. : Increased evidence of leprosy following HAART initiation: a manifestation of the immune reconstitution disease.AIDS23 , 1599–1600 (2009).
  • Rastogi N , LegrandE, SolaC: The mycobacteria: an introduction to nomenclature and pathogenesis.Rev. Sci. Tech.20 , 21–54 (2001).
  • Gutierrez MC , SupplyP, BroschR: Pathogenomics of mycobacteria.Genome Dyn.6 , 198–210 (2009).
  • Cole ST , BroschR, ParkhillJet al. : Deciphering the biology of M. tuberculosis from the complete genome sequence.Nature393 , 537–544 (1998).
  • Cole ST , EiglmeierK, ParkhillJet al. : Massive gene decay in the leprosy bacillus.Nature409 , 1007–1011 (2001).
  • Suzuki K , NakataN, BangPD, IshiiN, MakinoM: High level expression of pseudogenes in Mycobacterium leprae.FEMS Microbiol. Lett.259 , 208–214 (2006).
  • Han XY , SeoYH, SizerKCet al. : A new Mycobacterium species causing diffuse lepromatous leprosy.Am. J. Clin. Pathol.130 , 856–864 (2008).
  • Han XY , SizerKC, ThompsonEJet al. : Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis.J. Bacteriol.191 , 6067–6074 (2009).
  • Monot M , HonoréN, GarnierTet al. : Comparative genomic and phylogeographic analysis of Mycobacterium leprae.Nat. Genet.41 , 1282–1289 (2009).
  • Maiden MC : Putting leprosy on the map.Nat. Genet.41 , 1264–1266 (2009).
  • Gillis T , VissaV, MatsuokaMet al. : Characterization of short tandem repeats for genotyping Mycobacterium leprae.Lepr. Rev.80 , 250–260 (2009).
  • Kimura M , SakamuriRM, GroathouseNAet al. : Rapid variable-number tandem-repeat genotyping for Mycobacterium leprae clinical specimens.J. Clin. Microbiol.47 , 1757–1766 (2009).
  • Monot M , HonoreN, BaliereCet al. : Are variable-number tandem repeats appropriate for genotyping Mycobacterium leprae?J. Clin. Microbiol.46 , 2291–2297 (2008).
  • Alter A , AlcaïsA, AbelL, SchurrE: Leprosy as a genetic model for susceptibility to common infectious diseases.Hum. Genet.123 , 227–235 (2008).
  • Alcaïs A , AlterA, AntoniGet al. : Stepwise replication identifies a low-producing lymphotoxin-α allele as a major risk factor for early-onset leprosy.Nat. Genet.39 , 517–522 (2007).
  • Santos AR , SuffysPN, VanderborghtPRet al. : TNFα and IL-10 promoter polymorphisms in leprosy: association with disease susceptibility.J. Infect. Dis.186 , 1687–1691 (2002).
  • Mira MT , AlcaisA, diPietrantonio Tet al.: Segregation of HLA/TNF region is linked to leprosy clinical spectrum in families displaying mixed leprosy subtypes.Genes Immun.4 , 67–73 (2003).
  • Misch EA , MacdonaldM, RanjitCet al. : Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction.PLoS Negl. Trop. Dis.2 , E231–E239 (2008).
  • Cardoso CC , PereiraAC, Brito-de-SouzaVNet al. : IFNG +874 T>A single nucleotide polymorphism is associated with leprosy among Brazilians.Hum. Genet.128 , 481–490 (2010).
  • Mira MT , AlcaïsA, NguyenVTet al. : Susceptibility to leprosy is associated with PARK2 and PACRG.Nature427 , 636–640 (2004).
  • Johnson C , LyleEA, OmuetiKOet al. : Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.J. Immunol.178 , 7520–7524 (2007).
  • Bochud P-Y , HawnTR, AderemA: Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.J. Immunol.170 , 3451–3454 (2003).
  • Bochud P -Y, Hawn TR, Siddiqui MR et al.: Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J. Infect. Dis.197 , 253–261 (2008).
  • Morrison NA , QiJC, TokitaAet al. : Prediction of bone density from vitamin D receptor alleles.Nature367 , 284–287 (1994).
  • van Etten E , VerlindenL, GiuliettiAet al. : The vitamin D receptor gene FokI polymorphism: functional impact on the immune system.Eur. J. Immunol.37 , 395–405 (2007).
  • Roy S , FrodshamA, SahaBet al. : Association of vitamin D receptor genotype with leprosy type.J. Infect. Dis.179 , 187–191 (1999).
  • Sapkota BR , MacdonaldM, BerringtonWRet al. : Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes.Hum. Immunol.71 , 992–998 (2010).
  • Goulart LR , FerreiraFR, GoulartIM: Interaction of TaqI polymorphism at exon 9 of the vitamin D receptor gene with the negative lepromin response may favor the occurrence of leprosy.FEMS Immunol. Med. Microbiol.48 , 91–98 (2006).
  • Zhang FR , HuangW, ChenSMet al. : Genomewide association study of leprosy.N. Engl. J. Med.361 , 2609–2618 (2009).
  • Berrington WR , MacdonaldM, KhadgeSet al. : Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states.J. Infect. Dis.201 , 1422–1435 (2010).
  • van Beers SM , HattaM, KlatserPR: Patient contact is the major determinant in incident leprosy: implications for future control.Int. J. Lepr.67 , 119–128 (1999).
  • Moura RS , CaladoKL, OliveiraML, Bührer-SékulaS: Leprosy serology using PGL-I: a systematic review.Rev. Soc. Bras. Med. Trop.41(Suppl. 2) , 11–18 (2008).
  • Bührer-Sékula S , SmitsHL, GussenhovenGC, vanIngen CW, KlatserPR: A simple dipstick assay for the detection of antibodies to phenolic glycolipid-I of Mycobacterium leprae.Am. J. Trop. Med. Hyg.58 , 133–136 (1998).
  • Zenha EM , FerreiraMA, FossNT: Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients.Braz. J. Med. Biol. Res.42 , 968–972 (2009).
  • Bührer-Sékula S , IllarramendiX, TelesRBet al. : The additional benefit of the ML flow test to classify leprosy patients.Acta Trop.111 , 172–176 (2009).
  • Bührer-Sékula S , vanBeers S, OskamLet al.: The relation between seroprevalence of antibodies against phenolic glycolipid-I among school children and leprosy endemicity in Brazil.Rev. Soc. Bras. Med. Trop.41(Suppl. 2) , 81–88 (2008).
  • Martinez AN , BrittoCFPC, JardimMRet al. : Detection of Mycobacterium leprae DNA in skin biopsy samples of leprosy patients: evaluation of real time and conventional PCR targeting complex 85 genes.J. Clin. Microbiol.44 , 3154–3159 (2006).
  • Bang PD , SuzukiK, Phuongle Tet al.: Evaluation of polymerase chain reaction-based detection of Mycobacterium leprae for the diagnosis of leprosy.J. Dermatol.36 , 269–276 (2009).
  • Jardim MM , AntunesSG, WildenbeestJGet al. : PGL-I as an accessory test for the diagnosis of pure neural leprosy.Lepr. Rev.76 , 232–240 (2005).
  • Geluk A , vander Ploeg J, TelesROet al.: Rational combination of peptides derived from different Mycobacterium leprae proteins improves sensitivity for immunodiagnosis of M. leprae infection.Clin. Vaccine Immunol.15 , 522–533 (2008).
  • Spencer JS , DockrellHM, KimHJet al. : Identification of specific proteins and peptides in Mycobacterium leprae sui for the selective diagnosis of leprosy.J. Immunol.175 , 7930–7938 (2005).
  • Geluk A , vander Ploeg-van Schip JJ, vanMeijgaarden KEet al.: Enhancing sensitivity of detection of immune responses to Mycobacterium leprae peptides in whole-blood assays.Clin. Vaccine Immunol.17 , 993–1004 (2010).
  • Setia MS , SteinmausC, HoCS, RutherfordGW: The role of BCG in prevention of leprosy: a meta-analysis.Lancet Infect. Dis.6 , 162–170 (2006).
  • Düppre NC , CamachoLAB, CunhaSSet al. : Effectiveness of BCG vaccination among leprosy contacts: a cohort study.Trans. R. Soc. Trop. Med. Hyg.102 , 631–638 (2008).
  • Sharma P , MukherjeeR, TalwarGPet al. : Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8–10 years.Lepr. Rev.76 , 127–143 (2005).
  • Merle CS , CunhaSS, RodriguesLC: BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control.Expert Rev. Vaccines9 , 209–222 (2010).
  • Moet FJ , PahanD, OskamL, RichardusJH: Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial.BMJ336 , 761–764 (2008).
  • Schuring RP , RichardusJH, PahanD, OskamL: Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention.Vaccine27 , 7125–7128 (2009).
  • Bjune G , BarnetsonRS, RidleyDS, KronvallG: Lymphocyte transformation test in leprosy; correlation of the response with inflammation of lesions.Clin. Exp. Immunol.25 , 85–94 (1976).
  • Rea TH , LevanNE: Current concepts in the immunology of leprosy.Arch. Dermatol.113 , 345–352 (1977).
  • Khanolkar-Young S , RaymentN, BrickellPMet al. : Tumour necrosis factor-α (TNF-α) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions.Clin. Exp. Immunol.99 , 196–202 (1995).
  • Little D , Khanolkar-YoungS, CoulthartA, SuneethaS, LockwoodDN: Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12, and inducible nitric oxide synthase expression in leprosy type 1 (reversal) reactions before and during prednisolone treatment.Infect. Immun.69 , 3413–3417 (2001).
  • Stefani MM , GuerraJG, SousaALet al. : Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.BMC Infect. Dis.9 , 75–79 (2009).
  • Massone C , NunziE, Ribeiro-RodriguesRet al. : T regulatory cells and plasmocytoid dendritic cells in Hansen disease: a new insight into pathogenesis?Am. J. Dermatopathol.32 , 251–256 (2010).
  • Bjorvatn B , BarnetsonRS, KronvallG, ZublerRH, LambertPH: Immune complexes and complement hypercatabolism in patients with leprosy.Clin. Exp. Immunol.26 , 388–396 (1976).
  • Sreenivasan P , MisraRS, WilfredD, NathI: Lepromatous leprosy patients show T helper 1-like cytokine profile with differential expression of interleukin-10 during type 1 and 2 reactions.Immunology95 , 529–536 (1998).
  • Nath I , VemuriN, ReddiALet al. : The effect of antigen presenting cells on the cytokine profiles of s and reactional lepromatous leprosy patients.Immunol. Lett.75 , 69–76 (2000).
  • Moraes MO , SampaioEP, NeryJAC, SaraivaBCG, AlvarengaFBF, SarnoEN: Sequencial erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient.Brit. J. Dermatol.144 , 175–181 (2001).
  • Kahawita IP , LockwoodDN: Towards understanding the pathology of erythema nodosum leprosum.Trans. R. Soc. Trop. Med. Hyg.102 , 329–337 (2008).
  • Oliveira RB , MoraesMO, OliveiraEB, SarnoEN, NeryJA, SampaioEP: Neutrophils isolated from leprosy patients release TNF-α and exhibit accelerated apoptosis in vitro.J. Leukoc. Biol.65 , 364–371 (1999).
  • Lee DJ , LiH, OchoaMTet al. : Integrated pathways for neutrophil recruitment and inflammation in leprosy.J. Infect. Dis.201 , 558–569 (2010).
  • Barnes PF , ChatterjeeD, BrennanPJ, ReaTH, ModlinRL: Tumor necrosis factor production in patients with leprosy.Infect. Immun.60 , 1441–1446 (1992).
  • Hernandez MO , NevesI, SalesJS, CarvalhoDS, SarnoEN, SampaioEP: Induction of apoptosis in monocytes by Mycobacterium lepraein vitro: a possible role for tumour necrosis factor-α.Immunology109 , 156–164 (2003).
  • Oliveira RB , SampaioEP, AntasPRZ, TelesRMB, AarestrupF, SarnoEN. Cytokines and Mycobacterium leprae induce apoptosis in human Schwann cells. J. Neuropathol. Exp. Neurol.64 , 882–890 (2005).
  • Fulco TO , LopesUG, SarnoEN, SampaioEP, SalibaAM: The proteasome function is required for Mycobacterium leprae-induced apoptosis and cytokine secretion.Immunol. Lett.110 , 82–85 (2007).
  • Oliveira RB , OchoaMT, SielingPAet al. : Expression of Toll-like receptor 2 on human Schwann cells: a mechanism of nerve damage in leprosy.Infect. Immun.71 , 1427–1433 (2003).
  • Lahiri R , RandhawaB, KrahenbuhlJL: Infection of mouse macrophages with viable Mycobacterium leprae does not induce apoptosis.J. Infect. Dis.201 , 1736–1742 (2010).
  • Rambukkana A , ZanazziG, TapinosN, SalzerJL: Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells.Science296 , 927–931 (2002).
  • Yan N , RiccaC, FletcherJ, GloverT, SeizingerBR, ManneV: Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.Cancer Res.55 , 3569–3575 (1995).
  • Marques MA , AntônioVL, SarnoEN, BrennanPJ, PessolaniMC: Binding of α2-laminins by pathogenic and non-pathogenic mycobacteria and adherence to Schwann cells.J. Med. Microbiol.50 , 23–28 (2001).
  • Ng V , ZanazziG, TimplRet al. : Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae.Cell103 , 511–524 (2000).
  • Rambukkana A , YamadaH, ZanazziGet al. : Role of α-dystroglycan as a Schwann cell receptor for Mycobacterium leprae.Science282 , 2076–2079 (1998).
  • Rambukkana A , SalzerJL, YurchencoPD, TuomanenEI: Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin-α2 chain.Cell88 , 811–821 (1997).
  • Shimoji Y , NgV, MatsumuraK, FischettiVA, RambukkanaA: A 21-kDa surface protein of Mycobacterium leprae binds peripheral nerve laminin-2 and mediates Schwann cell invasion.Proc. Natl Acad. Sci. USA96 , 9857–9862 (1999).
  • Tapinos N , OhnishiM, RambukkanaA: ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli.Nat. Med.12 , 961–966 (2006).
  • Ribeiro-Resende VT , Ribeiro-GuimaraesML, LemesRMet al. : Involvement of 9-O-acetyl GD3 ganglioside in Mycobacterium leprae infection of Schwann cells.J. Biol. Chem.285(44) , 34086–34096 (2010).
  • Teles RM , AntunesSL, JardimMRet al. : Expression of metalloproteinases (MMP-2, MMP-9, and TACE) and TNF-α in the nerves of leprosy patients.J. Peripher. Nerv. Syst.12 , 195–204 (2007).
  • Oliveira AL , AntunesSL, TelesRMet al. : Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy.J. Neuropathol. Exp. Neurol.69 , 27–39 (2010).
  • Pereira RM , Calegari-SilvaTC, HernandezMOet al. : Mycobacterium leprae induces NF-κB-dependent transcription repression in human Schwann cells.Biochem. Biophys. Res. Commun.335 , 20–26 (2005).
  • Cardoso CC , MartinezAN, GuimarãesPEet al. : Ninjurin 1 asp110ala single nucleotide polymorphism is associated with protection in leprosy nerve damage.J. Neuroimmunol.190 , 131–138 (2007).
  • Schlesinger LS , HorwitzMA: Phagocytosis of Mycobacterium leprae by human monocyte-derived macrophages is mediated by complement receptors CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18) and IFN-γ activation inhibits complement receptor function and phagocytosis of this bacterium.J. Immunol.147 , 1983–1994 (1991).
  • Prabhakaran K , HarrisEB, RandhawaB: Regulation by protein kinase of phagocytosis of Mycobacterium leprae by macrophages.J. Med. Microbiol.49 , 339–342 (2000).
  • Soilleux EJ , MorrisLS, LeslieGet al. : Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro.J. Leukoc. Biol.71 , 445–457 (2002).
  • Geijtenbeek TB , van Kooyk Y: Pathogens target DC-SIGN to influence their fate: DC-SIGN functions as a pathogen receptor with broad specificity. APMIS111 , 698–714 (2003).
  • Maeda N , NigouJ, HerrmannJLet al. : The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan.J. Biol. Chem.278 , 5513–5516 (2003).
  • Krutzik SR , TanB, LiHet al. : TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells.Nat. Med.11 , 653–660 (2005).
  • Soilleux EJ , SarnoEN, HernandezMOet al. : DC-SIGN association with the Th2 environment of lepromatous lesions: cause or effect?J. Pathol.209 , 182–189 (2006).
  • Barreiro LB , QuachH, KrahenbuhlJet al. : DC-SIGN interacts with Mycobacterium leprae but sequence variation in this lectin is not associated with leprosy in the Pakistani population.Hum. Immunol.67 , 102–107 (2006).
  • Teles RM , KrutzikSR, OchoaMT, OliveiraRB, SarnoEN, ModlinRL: IL-4 regulates the expression of CD209 and subsequent uptake of Mycobacterium leprae by Schwann cells in human leprosy.Infect. Immun.78 , 4634–4643 (2010).
  • Kaplan G , WeinsteinDE, SteinmanRMet al. : An analysis of in vitro T cell responsiveness in lepromatous leprosy.J. Exp. Med.162 , 917–929 (1985).
  • Sarno EN , EspinosaM, SampaioEPet al. : Immunological responsiveness to M. leprae and BCG antigens in 98 leprosy patients and their household contacts.Braz. J. Med. Biol. Res.21 , 461–470 (1988).
  • Sieling PA , JullienD, DahlemMet al. : CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity.J. Immunol.162 , 1851–1858 (1999).
  • Agrewala JN , KumarB, VohraH: Potential role of B7–1 and CD28 molecules in immunosuppression in leprosy.Clin. Exp. Immunol.111 , 56–63 (1998).
  • Krutzik SR , OchoaMT, SielingPAet al. : Activation and regulation of Toll-like receptors 2 and 1 in human leprosy.Nat. Med.9 , 525–532 (2003).
  • Jain M , PetzoldCJ, SchelleMWet al. : Lipidomics reveals control of Mycobacterium tuberculosis virulence lipids via metabolic coupling.Proc. Natl Acad. Sci. USA104 , 5133–5138 (2007).
  • Sinsimer D , FallowsD, PeixotoB, KrahenbuhlJ, KaplanG, MancaC: Mycobacterium leprae actively modulates the cytokine response in naive human monocytes.Infect. Immun.78 , 293–300 (2010).
  • Alves L , deMendonça Lima L, daSilva Maeda Eet al.: Mycobacterium leprae infection of human Schwann cells depends on selective host kinases and pathogen-modulated endocytic pathways.FEMS Microbiol. Lett.238 , 429–437 (2004).
  • Sibley LD , KrahenbuhlJL: Mycobacterium leprae-burdened macrophages are refractory to activation by γ interferon.Infect. Immun.55 , 446–450 (1987).
  • Misra N , SelvakumarM, SinghSet al. : Monocyte derived IL-10 and PGE2 are associated with the absence of Th 1 cells and in vitro T cell suppression in lepromatous leprosy.Immunol. Lett.48 , 123–128 (1995).
  • Mellor AL , MunnDH: Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?Immunol. Today20 , 469–473 (1999).
  • Uyttenhove C , PilotteL, ThéateIet al. : Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.Nat. Med.9 , 1269–1274 (2003).
  • Popov A , SchultzeJL: IDO-expressing regulatory dendritic cells in cancer and chronic infection.J. Mol. Med.86 , 145–160 (2008).
  • Schröcksnadel K , WirleitnerB, WinklerC, FuchsD: Monitoring tryptophan metabolism in chronic immune activation.Clin. Chim. Acta364 , 82–90 (2006).
  • Liu PT , StengerS, LiHet al. : Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.Science311 , 1770–1773 (2006).
  • Montoya D , CruzD, TelesRMBet al. : Divergence of macrophage phagocytic and antimicrobial programs in leprosy.Cell Host Microbe6 , 343–353 (2009).
  • Cruz D , WatsonAD, MillerCSet al. : Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy.J. Clin. Invest.118 , 2917–2928 (2008).
  • Almeida PE , SilvaAR, Maya-MonteiroCMet al. : Mycobacterium bovis Bacillus Calmette-Guérin infection induces TLR2-dependent peroxisome proliferator-activated receptor γ expression and activation: functions in inflammation, lipid metabolism, and pathogenesis.J. Immunol.183 , 1337–1345 (2009).
  • Sampaio EP , MoraesMO, NeryJAC, SantosAR, MattosHJ, SarnoEN: Pentoxifylline decreases in vivo and in vitro TNFα production in lepromatous leprosy patients with ENL.Clin. Exp. Immunol.111 , 300–308 (1998).
  • Teles RM , MoraesMO, GeraldoNT, SallesAM, SarnoEN, SampaioEP: Differential TNFα mRNA regulation detected in the epidermis of leprosy patients.Arch. Dermatol. Res.294 , 355–362 (2002).
  • Sarno EN , SampaioEP, MoreiraAL, AlvarengaFBF: Isolation and functional characterization of mononuclear phagocytes from human lepromatous lesion.Rev. Soc. Bras. Med. Trop.20 , 205–207 (1987).
  • Moura DF , TelesRM, Ribeiro-CarvalhoMMet al. : Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae–human cell interaction.Br. J. Dermatol.157 , 273–283 (2007).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.